Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus osimertinib pharmacokinetics and exposure–response in EGFR-positive advanced NSCLC
ChiCTR2100048089Phase 4Not yet recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of osimertinib and anlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Objective response rate, Rate of adverse reaction and 1 more. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
osimertinibanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100048089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048089.